Preclinical and clinical studies have demonstrated that VEGF can be targeted to reduce angiogenesis and VEGF blockage has been shown to promote survival – especially when combined with chemotherapies – and slow tumor growth in ovarian, cervical, colorectal, renal, lung and breast cancer19. This evidence concerns the gene VEGFA and neoplasm.